“`html
On July 7, two stocks were highlighted for their strong buy rankings and momentum characteristics: Verona Pharma (VRNA) and Evolv Technologies (EVLV). Verona Pharma focuses on innovative therapeutics for chronic respiratory diseases and has a Zacks Rank of #1 (Strong Buy) with a 37.5% increase in the earnings estimate over the last 60 days. The company’s shares rose 69% over the last three months, outpacing the S&P 500’s gain of 26%.
Evolv Technologies offers AI touchless screening technologies and also holds a Zacks Rank of #1, with a 23.3% increase in earnings estimates in the same timeframe. Its shares surged 100.7% in the last three months, exceeding the S&P 500’s growth of 25.9%.
“`
